Source: Seekingalpha.com

Big pharma CEOs might wanna watch their backs because there could be a burgeoning power struggle in the C-suite. Ernst & Young, which has a long history of doing comprehensive reports on the pharmaceutical and biotech industries, is out with a new one today declaring that it's big pharma Chief Financial Officers who have all the mojo these days.

E & Y, which surveyed 95 C-suite honchos of companies around the world with at least a billion dollars in sales, calls the drug company CFO the "emerging 'star player' in the executive suite." The firm did the canvassing last fall.

To view the complete article, please visit www.seekingalpha.com.